About this document
A Frameshift Peptide Neoantigen-Based Vaccine For Mismatch Repair-De Cient Cancers: A Phase I/Iia Clinical Trial by aspace.forpersonal.privacy is a document available to read on EtoBox.
This document reports on a Phase I/IIa clinical trial evaluating the safety and immunogenicity of a frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers, particularly in patients with Lynch syndrome. The trial demonstrated that the vaccine induced immune responses in all patients vaccinated per protocol, with no severe adverse events reported. These findings suggest that FSP neoantigen vaccination is a promising approach for the treatment and prevention of MMR-deficient cancers.
- Author
- aspace.forpersonal.privacy
- Language
- EN